Mizuho raised the firm’s price target on ADMA Biologics to $10 from $9 and keeps a Buy rating on the shares. The analyst increased estimates following the company’s “beat and raise” quarter. The firm says demand for Asceniv continues to outpace supply.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADMA:
